SRX is a buy

High teen double digit growth as a baseline. What impact will a positive SARAH result have on dose sales? And then SIRFLOX/FOXFIRE? Both trials due to report within a year or so, with available data from related studies looking promising. Short term you might get them a bit cheaper, but medium to long term the SP is getting set to surge forward again.

I'm calling at least back over $40 by end of 2016, quite possibly much higher (over $50 possible) if SARAH is positive for OS. This is at least 25% above current SP. We can revisit with short seller calls later in the year to see who is on the money. SRX is a buy, if it gets cheaper it is even more of a buy